Hengrui Pharmaceutical announced that the subsidiary Ruishi Biopharmaceutical has received the “Drug Clinical Trial Approval Notice” for RSS0343 tablets from the State Drug Administration and will conduct clinical trials in the near future. The application for this drug is indicated for chronic sinusitis without nasal polyps and chronic obstructive pulmonary disease. RSS0343 is a new small-molecule class 1 drug independently developed by the company. No similar drug has been approved for marketing at home or abroad. The total R&D investment for related projects is about 72.28 million yuan. The drug development and marketing cycle is long, there are many steps, and there is uncertainty. The company will advance the project and disclose the progress.

Hengrui Pharmaceutical announced that the subsidiary Ruishi Biopharmaceutical has received the “Drug Clinical Trial Approval Notice” for RSS0343 tablets from the State Drug Administration and will conduct clinical trials in the near future. The application for this drug is indicated for chronic sinusitis without nasal polyps and chronic obstructive pulmonary disease. RSS0343 is a new small-molecule class 1 drug independently developed by the company. No similar drug has been approved for marketing at home or abroad. The total R&D investment for related projects is about 72.28 million yuan. The drug development and marketing cycle is long, there are many steps, and there is uncertainty. The company will advance the project and disclose the progress.